Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | HTR1D | P28221 | 3/20 | 0.38 |
| ▸ | HTR1B | P28222 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.38 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
| ▸ | HTR2B | P41595 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR1E | P28566 | 2/20 | 0.35 |
| ▸ | HTR1F | P30939 | 2/20 | 0.35 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.35 |
| ▸ | MLNR | O43193 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8721281 | 0.73 | HTR6 (0.37) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL8387410 | 0.69 | MLNR (0.36) | HTR1ADRD2HTR2ADRD3MLNR | |
| SCHEMBL8723706 | 0.67 | MLNR (0.36) | MLNR | |
| SCHEMBL7487112 | 0.67 | OPRM1 (0.43) | — | |
| SCHEMBL8725944 | 0.66 | HRH3 (0.34) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL30908788 | 0.66 | DRD2 (0.36) | DRD2HTR2ADRD3MLNR | |
| SCHEMBL30909193 | 0.64 | CYP2D6 (0.38) | — | |
| SCHEMBL8721040 | 0.64 | SIGMAR1 (0.35) | — | |
| SCHEMBL30909219 | 0.64 | SIGMAR1 (0.35) | — | |
| SCHEMBL5906394 | 0.62 | MAPK1 (0.38) | MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
| EP-0875513-A1 | Substituted heteroaromatic 5-HT 1F agonists | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR6 16/4885HTR1A 2/4885DRD2 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.